About: Drug repositioning: a brief overview

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Drug repositioning: a brief overview Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Drug repositioning: a brief overview
Creator	Bureau, Ronan Correspondence, Jean-Pierre Dallemagne, Patrick Jourdan, Jourdan, Jean-Pierre Rochais, Christophe
Source	Medline; PMC
abstract	OBJECTIVES: Drug repositioning, that is, the use of a drug in an indication other than the one for which it was initially marketed, is a growing trend. Its origins lie mainly in the attrition experienced in recent years in the field of new drug discovery. KEY FINDINGS: Despite some regulatory and economic challenges, drug repositioning offers many advantages, and a number of recent successes have confirmed both its public health benefits and its commercial value. The first examples of successful drug repositioning mainly came about through serendipity like acetylsalicylic acid, thalidomide, sildenafil or dimethylfumarate. CONCLUSION: The history of great‐repositioned drugs has given some solutions to various pathologies. Serendipity is not yet useful to find repositioning drugs. Drug repositioning is of growing interest. Nowadays, a more rational approach to the identification of drug candidates for repositioning is possible, especially using data mining.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1111/jphp.13273
bibo:pmid	32301512
has license	no-cc
sha1sum (hex)	36cdc1dd085744f8f7be8cf637a30abd741b5c64
schema:url	https://doi.org/10.1111/jphp.13273
resource representing a document's title	Drug repositioning: a brief overview
has PubMed Central identifier	PMC7262062
has PubMed identifier	32301512
schema:publication	J Pharm Pharmacol
resource representing a document's body	covid:36cdc1dd085744f8f7be8cf637a30abd741b5c64#body_text
is schema:about of	named entity 'ITS' named entity 'IN THE FIELD' named entity 'drug' named entity 'drug discovery' named entity 'return on investment' named entity 'drug repositioning' named entity 'Thalidomide' named entity 'gastrointestinal tract' named entity 'Europe' named entity 'limb development' named entity 'machine learning' named entity 'platelet aggregation' named entity 'serendipity' named entity 'Fumaderm' named entity 'rare disease' named entity 'intellectual property' named entity 'COX-2' named entity 'vasodilation' named entity 'anti-inflammatory' named entity 'cGMP' named entity 'pulmonary arterial hypertension' named entity 'thalidomide' named entity 'leprosy' named entity 'aspirin' named entity 'prostaglandins' named entity 'antiemetic' named entity 'signalling pathways' named entity 'aspirin' named entity 'first-line treatment' named entity 'sildenafil' named entity 'pleiotropic' named entity 'Sildenafil' named entity 'COVID-19' named entity 'drug repositioning' named entity 'toxicity' named entity 'Alzheimer's disease' named entity 'phocomelia' named entity 'levetiracetam' named entity 'Aspirin' named entity 'route of administration' named entity 'dihydropyridines' named entity 'antihypertensive drug' named entity 'aphrodisiac' named entity 'nitric oxide' named entity 'biological properties' named entity 'California' named entity 'sildenafil' named entity 'drug repositioning' named entity 'enzyme' named entity 'enzyme' named entity 'mould inhibitor' named entity 'teratogenicity' named entity 'thalidomide' named entity 'therapeutic effects' named entity 'cytoprotection' named entity 'intellectual property protection' named entity 'sildenafil' named entity 'enzyme' named entity 'pleiotropic' named entity 'oncology' named entity 'cardiotoxic' named entity 'drug repositioning' named entity 'orphan diseases' named entity 'oncology' named entity 'patent' named entity 'Marseille' named entity 'Jacob Sheskin' named entity 'pulmonary arterial hypertension' named entity 'Pfizer' named entity 'pharmaceutical industry' named entity 'Sildenafil' named entity 'methaemoglobinaemia' named entity 'drug repurposing' named entity 'platelet aggregation' named entity 'adverse effects' named entity 'generic drugs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software